Objective: We systematically reviewed the performance of 2010 WHO immunologic and clinical criteria for predicting virologic failure in HIV-infected patients on antiretroviral therapy (ART).
Introduction
Viral load monitoring has become the standard of care for monitoring the success of and diagnosing the failure of antiretroviral therapy (ART) in high-income countries [1] and has been explicitly recommended, when available, by the WHO since 2010 [2] . However, in most lowincome and many middle-income countries, viral load testing is not readily available, although some progress has been made in recent years [3] [4] [5] . In settings in which there is no access to viral load testing, clinical monitoring alone or a combination of clinical and immunologic monitoring is used to assess response to ART and determine treatment failure [6] .
WHO has developed simplified immunologic and clinical criteria to diagnose treatment failure and guide switches to second-line therapy. In 2006, there was one clinical criterion and one immunologic criterion, which were a new or recurrent WHO stage 4 condition, which is not immune reconstitution inflammatory syndrome (clinical criterion); and a fall in CD4 þ T cell count to baseline or below or a 50% fall in CD4 þ T cell count from on-treatment peak value or persistent CD4 þ T cell count levels below 100 cells/ml in the absence of concomitant infection that can cause a transient CD4 þ T cell count decline (immunologic criterion) [6] . The guidelines also suggested a plasma viral load threshold of 10 000 copies/ml as a threshold for defining virologic failure [6] . In 2010, the immunologic criterion was broadened to specify a 50% fall in CD4 þ T cell count levels from on-treatment peak value or persistent CD4 þ T cell count levels of less than 100 cells/ml after at least 24 weeks on ART in adults and children at least 5 years old or persistent CD4 þ T cell count levels of less than 200 cells/ml or CD4 þ T cell count less than 10% in 2-4-year-old children [2] . The clinical criterion was unchanged. The recommendations also lowered the definition of virologic failure to a threshold viral load of 5000 copies/ml [2] .
Five randomized controlled trials have assessed whether different monitoring strategies (laboratory vs. clinical) are associated with biological outcomes such as death and disease progression as well as unnecessary changes to second-line therapy [7] [8] [9] [10] [11] . Two studies, conducted in Uganda and Zimbabwe [7, 8] found that clinical monitoring was inferior to laboratory monitoring. The Uganda trial also compared clinical, immunologic, and virologic monitoring with clinical and immunologic monitoring and found no differences in mortality, disease progression, unnecessary switches, or virologic failure [8] .
Another study in Thailand found no difference in 3-year clinical outcomes using immunologic monitoring compared to viral load monitoring [9] . A study in Cameroon compared clinical monitoring alone to immunologic and virologic monitoring and found small benefits in immunologic recovery in participants who received laboratory monitoring, but not for other endpoints [10] . Additionally, a study in children less than 5 years old also conducted in Uganda and Zimbabwe found that immunologic monitoring, as opposed to clinical monitoring alone, was associated with a small mortality benefit after the first year of ART [11] . However, despite these findings and despite WHO's strong recommendation [2] , clinical and immunologic monitoring continue to be used.
To inform the 2013 WHO guidelines on the use of ART, we conducted a systematic review to assess how accurately WHO's 2010 clinical and immunologic criteria predicted virologic failure in studies using different viral load thresholds in adults and children.
Methods
We specified a priori our null hypothesis that the 2010 WHO clinical, immunologic, and clinical and immunologic criteria combined would be poorly predictive of virologic failure, as defined by more than 50 copies/ml, more than 1000 copies/ml, more than 5000 copies/ml, and more than 10 000 copies/ml. We included studies that assessed the performance of the 2010 WHO clinical criterion, immunologic criteria, and the clinical and immunologic criteria combined with respect to predicting virologic failure. Studies had to report sufficient data to calculate individual cell sizes and to allow at a minimum the calculation of a positive predictive value (PPV).
Search methods for identification of studies
Using Cochrane Collaboration methods [12] , we formulated a comprehensive and exhaustive search strategy in an attempt to identify all relevant studies. Databases searched included the Cochrane Central Register of Controlled Trials, Excerpta Medica Database (EMBASE), MEDLINE via PubMed, and WHO's Global Index Medicus. The search strategy included Medical Subject Heading (MeSH) terms and a range of relevant keywords. The search period was from 1 January 2006 to 15 November 2012 and was iterative in that references cited in included studies were searched for additional references. We also included studies from the gray literature, published in any language. Additionally, we searched for potentially relevant abstracts presented at key scientific conferences (the Conference on Retroviruses and Opportunistic Infections, the International AIDS Conference and the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention) within the search period. See Appendix 1 for our PubMed strategy, http://links.lww.com/QAD/ A493, which was modified and adapted for use with the other databases.
Selection of studies
We imported search results into a bibliographic citation management software (EndNote X4; Thomson Reuters, New York, New York, USA) and excluded duplicate references. Reviewing only article titles, one author (TH) excluded all references that were clearly irrelevant. Two authors (GWR and AA), working independently, then reviewed the titles, abstracts, and descriptor terms of the remaining citations to identify potentially eligible reports. We obtained full-text articles for all references identified that we judged potentially met inclusion criteria. GWR and AA reviewed these full-text articles and applied the inclusion criteria to establish each study's eligibility or ineligibility. Our plan was to resolve any differences of opinion through discussion and, if necessary, with a neutral third party arbiter, but we had no disagreements.
Data extraction and management
After identifying trials for inclusion, two authors (GWR and AA) working independently examined and extracted data from each study. GWR and AA separately entered these data into standardized data extraction forms and then compared the extracted data. There were no disagreements.
Assessment of methodological quality
We assessed methodological quality of included studies using methods developed for assessing the quality of studies of diagnostic test accuracy. We used the Cochrane Collaboration's 11-point adaptation [13] of the 14-point QUADAS instrument [14] , which includes items such as representativeness of the study sample, appropriateness of the verification procedure, blinding of test interpretation, and missing data.
Statistical analysis and data synthesis
We conducted separate analyses for adults and children. We calculated unweighted pooled sensitivity, specificity, PPV, and negative predictive value (NPV) for the 2010 WHO clinical criterion, the immunologic criteria, and either the clinical or the immunologic criteria in combination for descriptive purposes only, as pooled sensitivities and specificities can be misleading [15] . When there were adequate data reported within a study, we calculated all parameters. When only true-positive and false-positive test results were reported, we estimated only PPVs. As there are no comparable, clear-cut clinical criteria for treatment failure in children, we evaluated only the performance of immunologic criteria for predicting virologic failure. For adults, we analyzed three different viral load thresholds: a viral load of more than 50 to more than 1000 copies/ml, which represented the lower limits of detection at the time the studies were done; a viral threshold of more than 5000 copies/ml (the 2010 WHO definition); and a viral load threshold of more than 10 000 copies/ml (the 2006 WHO definition). For children, we analyzed virologic failure threshold of more than 400 copies/ml and more than 5000 copies/ml. Confidence intervals (CIs) for all estimates are exact binomial CIs [16] . We used R version 3.0.0 for the calculations [17] .
Results
Our searches initially yielded 3543 studies, of which 816 were duplicates. Of the remaining 2727 studies, 2299 were clearly irrelevant, leaving 428 studies. Of these, we reviewed 34 (7.9%) in detail. Twenty-five were in adults, and nine were in children. Fourteen (56.0%) of the adult studies and four (44.4%) of the pediatric studies met our inclusion criteria ( Fig. 1 , Table 1 ). The adult studies were from Africa [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] , Asia [30, 31] , and South America [23] , and the pediatric studies were from Africa [32] [33] [34] and Asia [35] . We excluded 16 studies because performance of the WHO criteria was not calculable from data presented [8, [36] [37] [38] [39] [40] [41] , authors evaluated different predictor variables than the WHO criteria [42] [43] [44] [45] [46] , authors used different outcomes such as mortality and disease progression [47] [48] [49] , or authors did not define virologic failure [50] .
Of the 14 studies in adults, 13 evaluated the clinical and immunologic criteria using lower plasma viral load values in adults, ranging from more than 50 to more than 1000 copies/ml [18] [19] [20] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . Three reported how well these criteria predicted a plasma viral load of more than 5000 copies/ml [22, 26, 28] ; one of these provided sufficient data to calculate PPV only [22] . Two studies evaluated a less stringent plasma viral load threshold of 10 000 copies/ml [24, 31] . Table 2 lists all study-specific data for each criterion.
Of the studies defining virologic failure based on threshold plasma viral loads between more than 50 and more than 1000 copies/ml in adults, 13 reported the performance of the 2010 WHO immunologic criteria [18] [19] [20] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] , seven the performance of the clinical criterion [19, [22] [23] [24] [29] [30] [31] , and seven the performance of either immunologic or clinical criteria [18, [22] [23] [24] [25] [29] [30] [31] (Table 1 ). In these studies, which involved 15 581 patients, the sensitivity estimates ranged from 13 to 91%, and the pooled sensitivity of the immunologic criteria was 54.9% (95% CI 52.9-56.9%). The specificity estimates ranged from 75 to 99%, and the pooled specificity was 82.9% (95% CI 82.2-83.5%). The PPV estimates ranged from 8 to 67%, whereas the pooled PPV was 38.0% (95% CI 36.4-39.6%). Finally, the NPV estimates ranged from 85 to 100%, and the pooled NPV was 90.9% (95% CI 90.4-91.4%). The sensitivity estimates for the clinical criterion ranged from 10 to 12%, and the pooled sensitivity for the clinical criterion was 11.0% (95% CI 5.7-19.7%). The specificity estimates ranged from 84 to 96%, and the pooled specificity was 90.5% (95% CI 88.2-92.3%). The PPVestimates ranged from 7 to 100%, and the pooled PPV was 44.9% (95% CI 38.2-51.8%). Finally, the NPVestimates ranged from 89 to 91% and the pooled NPV was 90.2% (95% CI 88.0-92.1%). Using either immunologic or clinical criteria, the sensitivity estimates ranged from 20 to 33%, and the pooled sensitivity was higher (26.6%, 95% CI 19.3-35.4%) than estimates using clinical criterion alone, but the specificity (85.9%, 95% CI 83.7-87.9%, range 86-87%), PPV (49.4%, 95% CI 45.1-53.6%, range 13-71%), and NPV (91.1%, 95% CI 89.2-92.8%, range 87-92%) were similar to those for the clinical criteria alone (Tables 2  and 3) .
Among the three studies that used a viral load threshold of more than 5000 copies/ml, the overall performance characteristics of the immunologic criteria were a sensitivity of 51.7% (95% CI 38.5-64.6%, range 28-88%), a specificity of 93.9% (95% CI 92.8-94.9%, range 90-98%), a PPV of 27.0% (95% CI 21.6-33.2%, range 8-57%), and an NPV of 98.6% (95% CI 98.0-99.9%, range 97-100%); of these, only PPV was calculated using data from all three studies [22, 26, 28] . One study reported the performance of clinical criteria and either immunologic or clinical criteria [22] . In this study, the clinical criterion had a PPV of 100% (based on a single patient), and either immunologic or clinical criteria had a PPV of 70.7% (95% CI 60.2-79.7%) based on 92 patients. The two studies that used a higher plasma viral load (>10 000 copies/ml) to define virologic failure assessed WHO immunologic criteria alone among 3142 patients [21, 28] . They found a pooled sensitivity of 16.8% (95% CI 11.3-24.1%, range 10-23%), a specificity of 95.5% (95% CI 94.6-96.2%, range 90-99%), a PPV of 15.0% (95% CI 10.0-21.7%, range 14-17%), and an NPV of 96.0% (95% CI 95.2-96.7%, range 94-97% (Tables 2 and 4 ).
Of the four pediatric studies we identified, three used more than 5000 copies/ml to define virologic failure [32, 34, 35] , and one used more than 400 copies/ml to define virologic failure [33] . The three studies that used more than 5000 copies/ml to define virologic failure evaluated 4100 patients and found a pooled sensitivity of 4.5% (95% CI 3.1-6.6%, range 4-7%), a pooled specificity of 99.3% (95% CI 99.0-99.6%, range 99-100%), a pooled PPV of 54.9% (95% CI 40.5-68.6%, range 49-100%), and a pooled NPV of 85.4% (95% CI 84.3-86.5%, range 73-86%). The one study that evaluated the 2010 criteria in 2256 children using a definition of virologic failure of more than 400 copies/ml found a sensitivity of 6.3% (95% CI 3.4-11.0%), a specificity of 97.7% (95% CI 96.9-98.3%), a PPV of 20% (95% CI 11.2-32.3%), and an NPV of 91.8% (95% CI 90.6-92.9%) [33] (Tables 2 and 4 ).
Methodological quality of included studies
The methodological quality of the studies we reviewed is mostly high (Appendix 2, http://links.lww.com/QAD/ A493). In nearly all studies, the sample of patients was representative, and although different thresholds were used, the reference standards of virologic failure were appropriate. There is no evidence of disease progression bias, that is, a bias arising from an inappropriately long delay between assessing the criteria and drawing the confirmatory tests. There is also no evidence of partial verification bias (selective testing of patients with the reference standard), differential verification bias (case confirmation using different reference standards), or incorporation bias (results of the case definition being used as a component of the reference standard). One study [18] reported that interpretation of test results was not blinded. This question was not addressed in any of the other papers, but, considering the studies' cross-sectional nature and laboratory test outcome (viral load), the lack of blinding is unlikely to be a source of bias. None of the included studies addressed the issue of uninterpretable test results. No study was reported to be sponsored by industry; no authors report having a conflict of interest. One published report [31] and three conference abstracts reported nothing regarding conflict of interest [19, 23, 32] .
Discussion
We found that the 2010 immunologic and clinical criteria for treatment failure have low sensitivity and PPV for identifying those with virologic failure, especially children. We also found that using a lower threshold to define virologic failure had minimal impact on performance of the WHO criteria. Our findings are consistent with current guidelines not only from WHO [51] but also from the United States Department of Health and Human Services [52] and the British HIV Association [53] , which recommend the use of plasma viral load monitoring to detect virologic failure and to guide changes in ART. However, we also note that there is a substantial randomized controlled trial literature that suggests immunologic or clinical and immunologic monitoring is not inferior to virologic monitoring when measured against clinical endpoints [8] [9] [10] [11] .
Our findings are subject to some limitations. First, as with all systematic reviews, we are limited by the sensitivity of our search and our ability to identify relevant studies. We comprehensively searched four key scientific databases and used broad inclusion criteria to identify studies. We carefully reviewed the bibliographies of included studies as well as abstracts from recent conferences to assure the completeness of our search. Second, we are potentially limited by publication bias, but given the largely poor performance reported for the WHO clinical and immunologic criteria's ability to predict virologic failure at any threshold, we suspect that publication bias was not an issue in this review. Nonetheless, we acknowledge that studies using more recent tests, which may not as yet have been published, might have yielded more favorable results. Additionally, commercially sponsored studies that produced less favorable results may not have been identified by our searches. Third, all pooled estimates are for descriptive purposes only and inference derived from the estimates should be carefully considered. Pooling sensitivities and specificities can be misleading [15] , and this is especially true with unweighted, pooled estimates, which may be misinterpreted as weighted, pooled estimates using random-effects or fixed-effects models. Finally, we adopted methods developed to assess the accuracy of diagnostic tests against a gold standard to assess the performance of a case definition against a laboratory outcome. However, the studies we reviewed often did not report methodological details that inform quality assessments of diagnostic tests [13] . Incomplete reporting in such studies could make it difficult to discern whether important aspects of conduct and design were adequate or whether the reporting of such aspects was inadequate [13] . In contrast to studies performed with the explicit aim of assessing diagnostic test accuracy, the studies we reviewed reported mostly retrospective data generated in the course of clinical practice in resource-limited settings, and, as such, explicit detail was largely missing, leading us to infer several quality criteria. Nonetheless, we believe that overall the literature we synthesize here is of generally high quality.
In conclusion, our findings highlight the poor diagnostic performance of the 2010 WHO clinical and immunologic criteria for predicting virologic failure. This
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